Identity
- Security key
- 13886
- Ticker
- CTNM
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2024-04-05
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- CTNM
Detail
Enriched 2026-08-14 20:47
- Market cap
- $563,564,557.36
- Shares outstanding (class)
- 32,958,632
- Shares outstanding (weighted)
- 37,621,132
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 51
- Location
- SAN DIEGO, CA
- Homepage
- https://www.contineum-tx.com
- Description
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
Market cap and share counts drift.